Inclusion Criteria:

- Age at diagnosis at least 4 years or 5 years (according to the policy of the National
Brain Tumour Group) and less than 22 years.

- Histologically proven medulloblastoma, including the following variants(WHO
classification - 2000): classic medulloblastoma, nodular / desmoplastic
medulloblastoma, melanotic medulloblastoma, medullomyoblastoma No CNS metastasis on
MRI - supratentorial, arachnoid of the posterior fossa or spine.

- No clinical evidence of extra-CNS metastasis

- No tumour cells on the cytospin of lumbar CSF. Central Review of CSF cytology is
recommended but not mandatory. It will be left to national policy.

- Radiotherapy to start no more than 40 days after surgery.

- Ability to receive twice daily radiotherapy.

- Vital functions within normal range for their age group.

- CTC grades < 2 for liver, renal, haematological and audiological function.

- No medical contraindication to radiotherapy or chemotherapy.

- Written informed consent (and patient assent where appropriate) according to the laws
of each participating country. Written informed consent should also be sought for
biological studies.

- National and local ethical committee approval according to the laws of each
participating country (to include approval for biological studies).

Exclusion Criteria:

- One of the inclusion criteria is lacking.

- Brainstem or supratentorial primitive neuroectodermal tumour.

- Atypical teratoid rhabdoid tumour.

- Medulloepithelioma.

- Ependymoblastoma.

- Large cell médulloblastoma.

- Metastatic medulloblastoma (on CNS MRI and/or positive cytospin of postoperative
lumbar CSF).

- Patient previously treated for a brain tumour or any type of malignant disease.

- Patients who are pregnant.

- Females who are sexually active and not taking reliable contraception.

- Known predisposition to medulloblastoma e.g. Gorlin's syndrome.